全文获取类型
收费全文 | 3586篇 |
免费 | 374篇 |
国内免费 | 156篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 18篇 |
妇产科学 | 56篇 |
基础医学 | 196篇 |
口腔科学 | 30篇 |
临床医学 | 235篇 |
内科学 | 230篇 |
皮肤病学 | 20篇 |
神经病学 | 73篇 |
特种医学 | 120篇 |
外国民族医学 | 1篇 |
外科学 | 265篇 |
综合类 | 542篇 |
预防医学 | 46篇 |
眼科学 | 1727篇 |
药学 | 147篇 |
中国医学 | 71篇 |
肿瘤学 | 313篇 |
出版年
2024年 | 9篇 |
2023年 | 57篇 |
2022年 | 69篇 |
2021年 | 134篇 |
2020年 | 124篇 |
2019年 | 98篇 |
2018年 | 113篇 |
2017年 | 117篇 |
2016年 | 149篇 |
2015年 | 137篇 |
2014年 | 193篇 |
2013年 | 233篇 |
2012年 | 196篇 |
2011年 | 250篇 |
2010年 | 248篇 |
2009年 | 250篇 |
2008年 | 241篇 |
2007年 | 268篇 |
2006年 | 249篇 |
2005年 | 220篇 |
2004年 | 163篇 |
2003年 | 117篇 |
2002年 | 102篇 |
2001年 | 73篇 |
2000年 | 43篇 |
1999年 | 36篇 |
1998年 | 30篇 |
1997年 | 27篇 |
1996年 | 19篇 |
1995年 | 15篇 |
1994年 | 15篇 |
1993年 | 8篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 6篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 12篇 |
1984年 | 12篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1970年 | 1篇 |
排序方式: 共有4116条查询结果,搜索用时 359 毫秒
1.
《Journal of Radiology Nursing》2022,41(2):123-128
ObjectiveThe objective of this study was to reduce errors in a pathologic specimen with the help of a protocol systematizing the pathology specimen management process in the operating room.Materials and methodThis quasi-experimental study was carried out in the operating room unit of a research and training hospital. A protocol systematizing the process of specimen management in secure surgical pathology and prepared in light of the current literature was used as an intervention, and the effectiveness of the protocol was tested.ResultsIt was determined that the rate of adverse events decreased from .3226% (68 of 21,078) to .032% (6 of 18,706) after the protocol systematizing the surgical pathology specimen management process prepared by the researchers, and the protocol was found to be effective by 90% (P = .03).ConclusionBased on the data obtained in this study, we recommend the use of a pathologic specimen management protocol in the operating room. 相似文献
2.
3.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献4.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献5.
6.
Fas/FasL在各阶段婴幼儿血管瘤中的表达及意义 总被引:15,自引:0,他引:15
目的 检测Fas/FasL在各阶段婴幼儿血管瘤组织中的表达,探讨Fas/FasL在婴幼儿血管瘤细胞凋亡中的作用。方法 应用EnVision法免疫组化染色和RT-PCR检测Fas/FasL蛋白及mRNA在各阶段血管瘤组织中的表达。结果 ①增生早期和增生中期,部分血管瘤细胞表达Fas;增生晚期,阳性细胞明显增多,Fas mRNA表达最强;消退早期,仍有少量微血管内皮细胞表达Fas,之后Fas表达迅速减弱。②最早期细胞团中没有FasL(+)细胞;增生中期,血管瘤组织中出现少量FasL(+)细胞;增生晚期FasL(+)细胞显著增多,FasL mRNA表达最强;消退早期之后,FasL(+)细胞迅速减少以至消失。结论 Fas/FasL与婴幼儿血管瘤演变过程有密切联系,Fas/FasL介导的血管瘤细胞凋亡可能是婴幼儿血管瘤自行消退的重要原因。 相似文献
7.
MMP-2、TIMP-2与碱烧伤后角膜新生血管形成的实验研究 总被引:1,自引:1,他引:0
目的:探讨基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-2组织型抑制剂(TIMP-2)在碱烧伤大鼠角膜新生血管(CNV)形成中的表达和意义。方法:采用碱烧伤大鼠角膜建立CNV模型,摘除角膜作病理切片,多形核白细胞(PMN)记数;免疫组化法检测MMP-2、TIMP-2的表达。结果:烧伤后1d角膜缘PMN开始增多,到CNV7d组PMN增加最明显,此后逐渐减少;免疫组化显示:MMP-2在CNV中阳性表达逐渐增加,于7d表达最明显,此后随炎性细胞的减少而减弱,21d后几乎无表达;TIMP-2则于早期变化不明显,7d表达开始升高,14d达高峰。结论:烧伤后CNV形成早期,MMP-2活性增高,继而TIMP-2表达增加,使MMP-2活性受抑,基底膜降解受阻,新生血管延伸停滞;CNV形成中,MMP-2的表达增加,并与角膜的炎性反应程度一致,PMN浸润可能是CNV形成的关键因素。 相似文献
8.
微波对白斑上皮异常增生12项病理特征出现率的影响 总被引:3,自引:1,他引:2
上皮异常增生是白斑癌变的必经阶段,深入研究其镜下形态的特征性改变,不仅对加深认识白斑癌变规律有利,而且可以籍以研究治疗手段的有效性,本文采用selly法白斑动物模型,以微波辐射为阻断手段,采集金地鼠颊囊标本,行光镜下肉眼观察,并按照WHO提出的上皮异常增生12项病理特征进行观察记录,结果发现:特征性改变的出现颊率不同,为15.5-60.6%,微波处理与否对病理的出现率存在影响,与细胞增殖有关的改变 相似文献
9.
胃癌动态增强MRI表现与肿瘤血管形成关系的研究 总被引:12,自引:1,他引:11
目的 探讨胃癌动态增强MRI强化表现与肿瘤血管形成的关系。方法 对 30例胃癌组织切片进行CD34和血管内皮生长因子 (VEGF)免疫组织化学染色。分析癌组织微血管密度 (MVD)和癌细胞VEGF的表达情况及其与临床病理特征的关系。并将动态增强MRI强化表现和扫描所获参数 (最大强化率 ,CERmax)与MVD、VEGF进行相关性研究。结果 30例胃癌组织的MVD平均值为(4 2 95± 14 79)个 /视野 ,范围为 13 0 0~ 6 8 2 5个 /视野。VEGF低表达 30 % (9/ 30 ) ,高表达 70 % (2 1/30 )。MVD和VEGF表达与有无淋巴结转移密切相关 (P <0 0 5 ) ,与组织分化程度、有无浆膜层受侵无关 (P >0 0 5 )。MVD与胃癌TNM各分期密切相关 (P <0 0 5 )。TNM分期中Ⅰ期与Ⅳ期间VEGF表达差异有显著意义 (P <0 0 5 )。VEGF高表达者MVD值 [(4 7 30± 14 16 )个 /视野 ]与VEGF低表达者MVD值 [(32 81± 11 2 5 )个 /视野 ]间差异有显著意义 (t=- 2 716 ,P =0 0 11)。CERmax与MVD呈正相关 (r=0 5 5 6 ,P =0 0 0 14 )。微血管的分布及形态与胃癌动态增强表现的不规则强化及分层强化类型存在一致性。CERmax与VEGF蛋白表达无明显相关性 (t=- 0 84 7,P =0 4 0 4 )。结论 胃癌动态增强MRI表现反映了胃癌微血管的分布和形态。动态增强MRI可 相似文献
10.
环缩酚肽抑制视网膜表达VEGF及PECAM基因和血管增生 总被引:2,自引:0,他引:2
[目的]观察两种环缩酚肽衍生物(Hep-A和Hep-B)对氧诱导的小鼠视网膜表达血管内皮生长因子(VEGF)和细胞黏附分子(PECAM;ICAM-1;VCAM-1)基因的影响及血管增生的变化.[方法]建立氧诱导的血管增殖性视网膜病变模型,12 d开始给小鼠皮下注安慰剂(第1组,n=7)、Hep-A 10 mg/kg(第2组,n=6)或者Hep-B 10 mg/kg(第3组,n=6),每天两次.5 d后取出左侧眼,分离视网膜并抽提RNA,用荧光定量PCR测出上述基因含量,并分别求出每个靶基因与标准基因S16含量的比率;右眼经心脏荧光素灌注后取眼球做视网膜平铺片,用图像分析软件定量计算视网膜新生血管的面积.[结果]视网膜中VEGF/S16的mRNA比率为:第1组(0.554±0.050),第2组(0.355±0.037),第3组(0.287±0.051);PECAM/S16为:第1组(2.050±0.249),第2组(1.228±0.153),第3组(1.027±0.210).经ANOVA分析,第2组和第3组分别与第1组比较,视网膜中VEGF基因表达分别减少36%和48.2%(P=0.001);PECAM基因表达分别减少40.1%(P<0.05)和49.9%(P<0.01);而VCAM-1和ICAM-1表达无明显差异.视网膜平片检测视网膜新生血管面积:第1组为(1.06±0.03)mm2/眼,第2组为(0.17±0.01)mm2/眼,第3组为(0.11±0.01)mm2/眼;经ANOVA分析,第2组和第3组分别与第1组比较,视网膜新生血管的面积明显减少(P<0.001).[结论]两种环缩酚肽衍生物均抑制氧诱导的小鼠视网膜表达VEGF和PECAM基因,并抑制其形成视网膜新生血管. 相似文献